



The Department of Gene & Cell Therapy
Akdeniz University

Tel +90 242 227 4400/3898
Cell +90 533 643 3765

ssanlioglu@icloud.com
<http://genetherapy.akdeniz.edu.tr/>

Salih Sanlioglu VMD, PhD

Profile	My main research interest is to find a cure for untreatable human genetic (diabetes, cancer, etc.) and infectious diseases (COVID-19) using virus-mediated (Adenovirus, AAV, and Lentivirus, etc.) gene and cell therapy approaches.
Experience	<i>The Head of the Department of Gene and Cell Therapy of Akdeniz University, 2019-Present</i>, Established Graduate Studies in Gene and Cell Therapy leading to M.S. and Ph.D. degrees. <i>Prof, Gene & Cell Therapy Center of Akdeniz University; Antalya – 2008-Present</i> Gene Therapy of Diabetes using HIV based Third Generation of Lentiviral Vectors encoding Glucagon Like Peptide-1 or Vaso Active Intestinal Peptide. <i>Asc. Prof, Gene & Cell Therapy Center of Akdeniz University; Antalya – 2003-2008</i> Gene and Islet Cell Therapy of Diabetes using First Generation of Adenovirus Vectors Encoding TRAIL. <i>Asst. Prof, Gene & Cell Therapy Center of Akdeniz University; Antalya – 2002-2003</i> Cancer Gene Therapy Using the First Generation of Adenoviral Vectors carrying Death Ligands. <i>Internal Medicine Research Fellow, Gene Therapy Center of University of Iowa, Iowa City, IA 52242, USA 1998-2001</i> Construction and Application of Adeno Associated Viral Vectors for Gene Therapy. <i>Post-Doctoral Fellow, Institute for Human Gene Therapy of University of Pennsylvania, PA 19104, USA 1997-1998</i> The efficacy of Adeno Associated Virus Mediated Gene Delivery into Murine Liver.
Education	Ph.D., MCDB Graduate Program, Ohio State University; College of Medicine, Columbus OH USA 1996. Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. Journal of Neuroscience 18(5):1763-73 1998. MS, MCDB Graduate Program, Ohio State University; College of Medicine, Columbus OH USA 1992.

Molecular cloning and characterization of two novel human genes (RP1 and RP2) located upstream of complement C4A and C4B in the HLA class III region. Journal of Biological Chemistry 269(11):8466-76, 1994.

VMD, Faculty of Veterinary Medicine, Selcuk University; Konya Turkey 1988 Trained as a Veterinary Medical Doctor.

Lectures	Gene Delivery Systems and Therapeutic Strategies, Principles of Medical Genetics, Research in Gene and Cell Therapy, Non-viral Gene Delivery Systems, Clinical Case Studies in Medical Genetics, Target Diseases in Gene and Cell Therapy, Clinical Applications of Gene and Cell Therapy, Cell and Gene Therapy, Gene Therapy Vectors: Methods, Principles of Gene Editing, Methods and Protocols in CRISPR Gene Editing, Gene Therapy Vectors: Protocols, Animal Models of Diabetes.
Projects	Gene therapy against retinal degeneration <i>TUBITAK 218S543</i> . Insulin Gene Therapy. <i>TUBITAK 215S820</i> ; Therapeutic efficacy of an HIV based lentivirus vector encoding wildtype human glucagon-like peptide-1 in an experimental animal model of type 2 diabetes. <i>TUBITAK 112S114</i> ; Therapeutic efficacy of pancreatic beta cell-specific vasoactive intestinal peptide expression in diabetic animals with beta-cell dysfunction and islet cell loss. <i>TUBITAK 111S157</i> ; Genetic modification of pancreatic islets using adenovirus-mediated TRAIL gene delivery for Type 1 Diabetes. <i>TUBITAK 104S224</i> .
Membership	American Society for Gene and Cell Therapy (ASGCT), European Society for Gene and Cell Therapy (ESGCT), Turkish Society of Gene and Cell Therapy (TSGCT), Turkish Society of Medical Genetics, Turkish Society of Medical Biology and Genetics
Refereed Journals	Gene Therapy, Human Gene Therapy, Journal of Gene Medicine, Current Gene Therapy, Diabetes, Journal of Urology, Nature Clinical Practice Oncology, Cancer Letters, Cell Death and Differentiation, Cancer Biology and Therapy, Cancer Detection and Prevention, Cancer Informatics, Expert Review of Dermatology, Future Virology, Journal of Cell Biology, Journal of Pharmacy and Pharmacology, Transplant Immunology, BMC Cancer, Molecular and Cellular Biochemistry, Current Pharmaceutical Biotechnology, Türkiye Klinikleri Tıp Bilimleri Dergisi, etc.
Grant Reviewer	European Union Framework Programs; American Association for Cancer Research; International Cancer Technology Transfer Fellowships (ICRETT); Translational Cancer Research Fellowships (TCRF); Irish Health Research Board Grant Review, TUBITAK.
Awards	Gold Medal 3 rd İstanbul International Inventions Fair 2018, Oral presentation award 1st place, 53rd National Diabetes Congress, Cyprus 2017; 12th National Medical Genetics Congress 1st place Poster Award, Çeşme İzmir, 2016; 14th National Medical Biology and Genetics Congress, oral presentation 2nd place, Fethiye, Muğla 2015; Diabetes Mellitus Publication Award 2nd place 2013; Diabetes Mellitus Publication Award 1st place 2010; Altan Gunalp Medical Research Award 1st place 2009; Altan Gunalp Medical Research Award 3rd place 2009; National Head and Neck Surgery Congress 1st place 2009; 6th

Metabolic syndrome symposium Poster Award 1st place 2009; Novartis Diabetes Research Award 2009; 11th European Endocrinology Congress Investigator Award 2009; Akdeniz University Scientific Achievement Award 2007; Altan Gunalp Medical Research Award 1st place 2007; 43rd National Diabetes Congress Poster Award 2nd place 2007; European Union Framework Program Project Proposal Submission Encouragement Award 2005; Abbott Rheumatoid Arthritis Research Award 2nd place 2005; TUBITAK Investigator Career Project Award 2004; Schering-German Urooncology Award 1st place 2004; Schering-German Urooncology Award 3rd place 2003; Altan Gunalp Medical Research Award 1st place 2003; Highest Caliber in Medical Research University of Iowa College of Medicine 2000; National Research Service Award U.S. National Institute of Health Bethesda Maryland 1998; Excellence in Scientific Presentation 18th annual meeting of Graduate Student Forum ICSABER Society of the Ohio State University Columbus Ohio; Excellence in Scientific Presentation Children's Hospital Research Foundation The Ohio State University Columbus Ohio 1992.

Trained Fellows

Fulya Erendor MS, PhD, Elif Ozgecan Sahin MS, Bahar Akkaya MS, M. Hale Tasyurek PhD, Yunus Emre Eksi PhD, Hazal Banu Olgun MS, Ahter D. Sanlioglu PhD, Ercument Dirice PhD, Atil Bisgin MD PhD, Cigdem Aydin Acar PhD, Sevim Kahraman MS, Duygu Yasar MS, Peter K. Benson MD, Carl W. Williams MD

Publications

1. Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes. Erendor F, Eksi YE, Sahin EO, Balci MK, Griffith TS, Sanlioglu S. *Mol Ther.* 2021 Jan 6;29(1):149-161. doi: 10.1016/j.ymthe.2020.10.025. PMID: 33130311.
2. Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Erendor F, Sahin EO, Sanlioglu AD, Balci MK, Griffith TS, Sanlioglu S. *Gene Ther.* 2020 Jul 30. doi: 10.1038/s41434-020-0183-3. Online ahead of print. PMID: 32733091
3. High-grade purification of third-generation HIV-based lentiviral vectors by anion exchange chromatography for experimental gene and stem cell therapy applications. Olgun HB, Tasyurek HM, Sanlioglu AD, and Sanlioglu S. *Springer Nature Experiments. Methods Mol Biol.* 2019;1879:347-365. DOI: 10.1007/7651_2018_154. Humana Press, New York, NY
4. High titer production of HIV-based Lentiviral Vectors in roller bottles for Gene and Cell therapy. Olgun HB, Tasyurek HM, Sanlioglu AD, and Sanlioglu S. *Springer Nature Experiments. Methods Mol Biol.* 2019;1879:323-345. DOI: 10.1007/7651_2018_150 Humana Press, New York, NY
5. Aydin C., Bisgin A., Sanlioglu AD., Pestereli E., Erdogan G., Ozbudak IH., Simsek T., Sanlioglu S. Expression profiles of TRAIL and its receptors in normal, hyperplastic, and malignant endometrial tissues: Hints on endometrial cancer biology. *Eastern Journal of Medicine*, 2019, 24(3); 361-370.
6. Therapeutic potential of lentivirus-mediated glucagon-like peptide-1 (GLP-1) gene therapy for diabetes. Tasyurek HM, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. *Hum Gene Ther.* 2018 Jul;29(7):802-815. DOI: 10.1089/hum.2017.180. Epub 2018 Mar 20.
7. HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against the DIO animal model of Type 2 diabetes. Tasyurek MH, Eksi YE, Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. *Gene Therapy*, 2018 Jul;25(4):269-283. DOI: 10.1038/s41434-018-0011-1. Epub 2018 Mar 9.
8. Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with the upregulation of death receptors. Timur M, Cort A, Ozdemir E, Sarikcioglu SB, Sanlioglu S, Sanlioglu AD, Ozben T. *Anticancer Agents Med Chem.* 2015;15(1):99-106.
9. Incretins: Their Physiology and Application in the Treatment of Diabetes Mellitus. Tasyurek HM, Altunbas HA, Balci MK, and Sanlioglu S. *Diabetes Metab Res Rev.* 2014 Jul;30(5):354-71. DOI: 10.1002/dmrr.2501
10. GLP-1-mediated gene therapy approaches for diabetes treatment. Tasyurek MH, Altunbas HA, Canatan H, Griffith TS, Sanlioglu S. *Expert Rev Mol Med.* 2014 Mar 26;16:e7. DOI: 10.1017/erm.2014.7.
11. Clinical utility of insulin and insulin analogs. Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. *Islets.* 2013 Mar-Apr;5(2):67-78. PMID: 23584214
12. Insulin Gene Therapy From Design to Beta Cell Generation. Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, and Sanlioglu S. *Expert Rev Mol Med.* 2012 Oct 15;14:e18. DOI: 10.1017/erm.2012.12. PMID: 23062285

13. Therapeutic Potential of VIP versus PACAP in Diabetes. Sanlioglu AD, Karacay B, Balci MK, Griffith TS, and Sanlioglu S. *J Mol Endocrinol* 2012 Oct 12;49(3): R157-67. DOI: 10.1530/JME-12-0156. Print 2012 Dec. PMID: 22991228
14. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. *BMC Cancer*. 2012 Feb 7;12(1):58.
15. TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- versus CY-Applied NOD Mice. Dirice E, Kahraman S, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. *Experimental Diabetes Research*. 2011 Art No: 625813 DOI: 10.1155/2011/625813.
16. Tracing of xenogeneic islet graft survival by way of in vivo fluorescence imaging. Kahraman S, Dirice E, Hapil FZ, Ertosun MG, Ozturk S, Griffith TS, Sanlioglu S, and Sanlioglu AD. *Diabetes Metab Res Rev* 2011 27(6):575-83.
17. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith TS, Sanlioglu S, Ozluoglu LN. *Head Neck*. 2011 33(9):1278-84.
18. NF-kappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, Karacay B, Griffith TS, and Sanlioglu S. *BMC Cancer*. 2010, 10:584
19. TRAIL Death Receptor-4, Decoy Receptor-1, and Decoy Receptor-2 Expression on CD8+ T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis. Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S. *BMC Musculoskelet Disord*. 2010 Aug 27;11:192.
20. Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer. Koksall IT, Sanlioglu AD, Kutlu O, Sanlioglu S. *Urol Int*. 2010;84(4):445-51.
21. Importance of TNF-related apoptosis-inducing ligand in the pathogenesis of interstitial cystitis. Kutlu O, Akkaya E, Koksall IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S, Kukul E. *Int Urol Nephrol*. 2010 Jun;42(2):393-9.
22. In Vivo Fluorescence Imaging is Well-Suited for the Monitoring of Adenovirus Directed Transgene Expression in Living Organisms. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Bagci H, Erkilic M, Griffith TS and Sanlioglu S. *Molecular Imaging and Biology*. 2010 Jun; 12 (3):278-85.
23. Adenovirus mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Ozturk S, Balci MK, Omer A, Griffith TS and Sanlioglu S. *Human Gene Therapy*. Oct 2009, 20(10): 1177-1189
24. CTLA-4 gene polymorphism of exon 1(+49 A/G) in Turkish systemic lupus erythematosus patients. Ulker M, Yazisiz V, Sallakci N, Avci AB, Sanlioglu S, Yegin O, Terzioglu E. *Int J Immunogenet*. 2009 Aug;36(4):245-50
25. High TRAIL Death Receptor-4 (DR4) and Decoy Receptor-2 (DcR2) expression correlates with significant cell death in pancreatic ductal adenocarcinoma (PDAC) patients. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu S. *Pancreas* 2009 Mar;38(2):154-60.
26. Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Korcum AF, Sanlioglu S, Aksu G, Tuncel N, Erin N. *Molecular Medicine Reports* 2009 Mar-Apr; 2(2): 319-326.
27. Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Sanlioglu AD, Griffith TS, Omer A, Dirice E, Sari R, Altunbas HA, Balci MK, and Sanlioglu S. *J Cell Biochem* 2008 June 1; 104(3):710-720.

28. High levels of endogenous TRAIL expression correlate with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS and Sanlioglu S. *Pancreas* 2008 May; 36(4):385-393.
29. TRAIL-R4 decoy receptor gene expression is correlated with high Gleason scores, PSA recurrence and decreased survival in patients with prostate carcinoma. Koksall IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. *Urologic Oncology* 2008 Mar-Apr; 26(2):158-165.
30. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Sanlioglu AD, Karacay B, Koksall IT, Griffith TS and Sanlioglu S. *Cancer Gene Therapy*. 2007 Dec; 14(12):976-984.
31. Corneal protein nitration in experimental uveitis. Aslan M, Yucel I, Akar Y, Yücel G, Ciftcioglu MA and Sanlioglu S. *Exp Biol Med (Maywood)*. 2007 Nov; 232(10): 1308-1313.
32. TRAIL death receptor-4 (DR4) expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. *Int J Radiat Oncol Biol Phys*. 2007 Nov; 69(3): 716-723.
33. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, and Sanlioglu S. *Rheumatology (Oxford)*. 2007 May; 46(5): 783-789.
34. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. *Human Gene Therapy*. 2007 Jan; 18: 39-50.
35. Dajani R, Sanlioglu S, Zhang Y, Li Q, Monick MM, Lazartigues E, Eggleston T, Davisson RL, Hunninghake GH, Engelhardt JF. Pleiotropic Functions of TNF alpha Determine Distinct IKK beta-Dependent Hepatocellular Fates in Response to LPS. *Am J Physiol Gastrointest Liver Physiol*. 2007 Jan; 292(1): G242-252.
36. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. Sanlioglu AD, Koksall IT, Ciftcioglu MA, Baykara M, Luleci G and Sanlioglu S. *Journal of Urology*. 2007 Jan; 177(1): 359-364.
37. Nitrotyrosine Formation and Apoptosis in Rat Models of Ocular Injury. Aslan M, Yucel I, Akar Y, Yücel G, Çiftçioglu MA and Sanlioglu S. *Free Radical Research*. 2006 Feb; 40(2): 147-153.
38. Adenovirus mediated IKK β KA expression sensitizes prostate carcinoma cells to TRAIL induced apoptosis. Sanlioglu AD, Koksall IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. *Cancer Gene Therapy*. 2006 Jan; 13(1): 21-31
39. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. *BMC Cancer*. 2005 25;5(1):54
40. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Koksall IT, Yasar D, Dirice E., Usta MF, Karauzum S, Luleci G, Baykara M and Sanlioglu S. *Urol Int*. 2005 75(2): 102-106
41. The effect of cetirizine on IFN - γ ve IL – 10 production in children with allergic rhinitis. Uguz A, Sanlioglu S, Yuzbey S, Coskun M, Yegin O. *Turkish Journal of Pediatrics*. 2005 47: 111-115
42. Inhibition of the NF-kB Pathway Enhances TRAIL-Mediated Apoptosis in Neuroblastoma Cells. Karacay B, Sanlioglu S, Griffith TS, Sandler A and Bonthius DJ. *Cancer Gene Therapy*. 2004 Oct; 11(10): 681-690.
43. Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Sanlioglu AD, Karacay B, Benson PK, Engelhardt JF and Sanlioglu S. *Virus Research*. 2004 Aug; 104(1): 51-59.

44. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Koksall IT., Dirice E, Yasar D, Sanlioglu AD, Gulkesen KH, Ciftcioglu A., Ozes ON, Baykara M, Luleci G and Sanlioglu S. *Urol Oncol*. 2004 22(4): 307-312.
45. Fundamental Principles of Tumor Necrosis Factor- α gene therapy approach and implications for patients with lung carcinoma. Sanlioglu AD, Aydin C, Bozcuk H, Terzioğlu E and Sanlioglu S. *Lung Cancer*. 2004 44: 199-211.
46. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Sanlioglu AD, Koksall T, Baykara M, Luleci G, Karacay B, Sanlioglu S. *Gene Ther Mol Biol*. 2003 7: 113-133.
47. Genetic redox preconditioning differentially modulates AP-1 and NF κ B responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Yang J, Marden JJ, Fan C, Sanlioglu S, Weiss RM, Ritchie TC, Davisson RL, Engelhardt JF. *Molecular Therapy*. 2003 Mar;7(3): 341-353
48. First generation adenovirus vectors shorten survival time in a murine model of sepsis. Sanlioglu, S, Doerschug K, Flaherty, DM, Wilson RL, Yarovinsky TO, Monick MM, Engelhardt JF and Hunninghake GW. *J. Immunology*. 2002 169: 6539-6545.
49. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, and Hunninghake GW. *Am J Physiol Cell Physiol*. 2002 Jul;283(1): C273-81.
50. Simultaneous inhibition of Rac1 and IKK Pathways sensitizes lung cancer cells to TNF α mediated apoptosis. Sanlioglu S, Luleci G and Thomas KW. *Cancer Gene Therapy*. 2001 8(11): 897-905.
51. GPx-1 gene delivery modulates NF κ B activation following diverse environmental injuries through a specific subunit of the IKK complex. Li Q, Sanlioglu S, Li S, Ritchie T, Oberley L and Engelhardt JF. *Antioxidant and Redox Signaling*. 2001 3(3): 415-431.
52. LPS induces Rac1 dependent reactive oxygen species (ROS) formation and coordinates TNF α secretion through IKK regulation of NF κ B. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Ritchie TC, Hunninghake GW, Zandi E and Engelhardt JF. *JBC*. 2001 Aug 276(32): 30188-30198.
53. Rate Limiting Steps of AAV transduction and Implications for Human Gene Therapy. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW and Engelhardt JF. Review. *Current Gene Therapy*. 2001 June; 1(2): 137-147.
54. Endocytosis and Nuclear Trafficking of Adeno-Associated Virus Type-2 is Controlled by Rac1/PI3-kinase Activation. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T and Engelhardt JF. *Journal of Virology*. 2000 Oct; 74(19): 9184-9196 (Cover illustration)
55. Loss of ATM Function Enhances Recombinant Adeno-Associated Virus Transduction and Integration through Pathways Similar to UV Irradiation. Sanlioglu S, Benson P, Engelhardt JF. *Virology*. 2000 Mar 1; 268(1): 68-78 (Cover illustration)
56. Two Independent Molecular Pathways for Recombinant Adeno-Associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Sanlioglu S, Duan D and Engelhardt JF. *Human Gene Therapy*. 1999 March 1; 10(4): 591-602.
57. Cellular Redox State Alters Recombinant Adeno-Associated Virus Transduction Through Tyrosine Phosphatase Pathways. Sanlioglu S and Engelhardt JF. *Gene Therapy*. 1999 6: 1427-1437.

58. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4-ORF6 and E2a gene expression. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Lester R, Yang J, Fisher KJ, Engelhardt, J.F. *Journal of Virology*. 1999 73(1): 161-169.
59. Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells. Baader SL, Vogel MW, Sanlioglu S, Zhang X, Oberdick J. *Journal of Neuroscience*. 1999 Jul 1; 19(13): 5370-5379.
60. Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, Zhang X, Baader SL, Oberdick J. *Journal of Neurobiology*. 1998 Sep 15; 36(4): 559-571.
61. Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. Sanlioglu S, Baader SL, Berrebi AS, Parker-Thornburg J, Oberdick J. *Journal of Neuroscience*. 1998 Mar 1; 18(5): 1763-1773.
62. Functional cloning of candidate genes that regulate Purkinje cell-specific gene expression. Sanlioglu S. and Oberdick J. *Progress in Brain Research*. 1997 114: 3-19.
63. Local control of granule cell generation by cerebellar Purkinje cells. Smeyne R, Chu T, Lewin A, Bian F, Sanlioglu S, Kunsch C, Lira SA and Oberdick J. *Mol Cell Neuroscience*. 1995 6: 230-251.
64. Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and C4B genes in the HLA class III region. Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel A, Carroll MC, Zipf WB, Yung CY. *Journal of Biological Chemistry*. 1994 269(11): 8466-8476.
65. Isolation of *Acinetobacter lwoffii* from hens with septicemia Kaya O, Ates M, Erganis O, Corlu M. and Sanlioglu S. *Journal of Veterinary Medicine*. 1989 36(2): 157-158.

International Meeting Abstracts

1. Lentivirus mediated insulin promoter directed insulin gene expression is effective in suppressing postprandial glucose excursions in Type 1 diabetes. Eksi YE, Erendor F, Sahin EO, Balci MK, and Sanlioglu S. ESGCT 27th Annual Congress in collaboration with SETGyc. Human Gene Therapy. Vol: 30 issue: 11. Meeting Abstract: A154-A155. P463. Barcelona, SPAIN, OCT 22-25, 2019.
2. LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes. Erendor F, Sahin EO, Balci MK, and Sanlioglu S. ESGCT 27th Annual Congress in collaboration with SETGyc. Human Gene Therapy. Vol: 30 issue: 11. Meeting Abstract: A35-A36. P059. Barcelona, SPAIN, OCT 22-25, 2019.
3. New gene therapy modalities targeting oxidative stress and microglial activation are needed for effective treatment of retinitis pigmentosa. Sahin EO, Erendor F, Bilgin AB, Ceylaner S, and Sanlioglu S. ESGCT 27th Annual Congress in collaboration with SETGyc. Human Gene Therapy. Vol: 30 issue: 11. Meeting Abstract: A113-A113. P320. Barcelona, SPAIN, OCT 22-25, 2019.
4. GLP-1 gene delivery stimulates cellular proliferation and trans-differentiation of pancreatic cells in type 2 diabetes. Tasyurek HM, Altunbas HA, Balci MK, and Sanlioglu S. ESGCT XXVI Anniversary Congress. CHANGING THE FACE OF MODERN MEDICINE: STEM CELLS & GENE THERAPY. Meeting Abstract: A132. P356. Lausanne, Switzerland OCT 16-19, 2018
5. Generation of insulin deficient pancreatic beta cells for insulin gene replacement therapy. Eksi YE, Balci MK, and Sanlioglu S. ESGCT XXVI Anniversary Congress. CHANGING THE FACE OF MODERN MEDICINE: STEM CELLS & GENE THERAPY. Meeting Abstract: A114. P295. Lausanne, Switzerland OCT 16-19, 2018
6. Intraperitoneal delivery of LentiINS vector lowered fasting plasma glucose and improved glucose tolerance of type 1 diabetic Wistar rats. Erendor F, Sahin EO, Balci MK and Sanlioglu S. ESGCT XXVI Anniversary Congress. CHANGING THE FACE OF MODERN MEDICINE: STEM CELLS & GENE THERAPY. Meeting Abstract: A129. P347. Lausanne, Switzerland OCT 16-19, 2018
7. Generation of a Novel Gene Therapy Vector Encoding Beta Cell Specific Insulin for Diabetes Treatment. Sahin EO, Erendor F, Balci MK and Sanlioglu S. 78th Congress of American Diabetes Association. June 22-26 2018 Orlando Florida USA.
8. Development of MODY10 diabetic experimental animal model using CRISPR/Cas9 technology for insulin gene transfer studies. Eksi Y, Altunbas HA and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages: A48-A49 Meeting Abstract: P112. Berlin, Germany OCT 17-20, 2017
9. Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulinitis and hyperglycaemia useful for gene transfer studies. Sahin EO, Erendor F, Balci MK and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A49 Meeting Abstract: P113. Berlin, Germany OCT 17-20, 2017
10. Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes. Erendor F, Sahin EO, Balci MK and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A59-A60 Meeting Abstract: P152. Berlin, Germany OCT 17-20, 2017

11. A practical method for production and purification of 3rd generation HIV based lentiviral vectors for In vivo applications. Olgun HB, Balci MK and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A65 Meeting Abstract: P176. Berlin, Germany OCT 17-20, 2017
12. Glucagon like peptide-1 as an antidiabetic gene therapy agent inducing transdifferentiation of pancreatic endocrine cells. Tasyurek H, Altunbas HA and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A93 Meeting Abstract: P277. Berlin, Germany OCT 17-20, 2017
13. Generation of a beta cell specific insulin gene therapy vector for diabetes. Sahin EO, Erendor F, Balci MK and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A110 Meeting Abstract: P341. Berlin, Germany OCT 17-20, 2017
14. Development of a gene therapy vector to provide insulin expression from induced pluripotent stem cells. Gumuslu E, Balci MK and Sanlioglu S. ESGCT XXV Anniversary Congress. Human Gene Therapy. Volume:28 Issue:12 Pages:A115 Meeting Abstract: P357. Berlin, Germany OCT 17-20, 2017
15. Generation of a lentiviral vector encoding human insulin for diabetes treatment. Eksi Y, Balci MK and Sanlioglu S. Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy. Human Gene Therapy. Volume: 27 Issue: 11 Pages: A156-A156 Meeting Abstract: P363 Florence, ITALY OCT 18-21, 2016
16. Novel approaches for insulin mediated gene delivery in diabetes treatment. Eksi Y, Balci MK and Sanlioglu S. Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy. Human Gene Therapy. Volume: 27 Issue: 11 Pages: A156-A156 Meeting Abstract: P361 Florence, ITALY OCT 18-21, 2016
17. Glucagon like peptide-1 gene delivery increases beta cell replication and neogenesis in Type 2 Diabetic Obese Sprague Dawley Rats. Tasyurek H, Altunbas HA and Sanlioglu S. Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy. Human Gene Therapy. Volume: 27 Issue: 11 Pages: A156-A156 Meeting Abstract: P362 Florence, ITALY OCT 18-21, 2016
18. Current progress in incretin based gene therapy approaches for diabetes. Sanlioglu S. Medical Genetics and Clinical Applications. Erciyes Medical Journal. March 2016 38 (2): SP17. Kayseri, Turkiye.
19. Vasoactive intestinal peptide gene delivery for diabetes treatment. Tasyurek H, Balci MK and Sanlioglu S. İstanbul Technical University, Molecular Biology and Genetics Congress. İstanbul, Turkey October 2-4 2015.
20. Therapeutic outcomes of an HIV-based lentivirus mediated Glucagon-like peptide-1 gene delivery for diabetes treatment. Tasyurek H, Altunbas HA, Canatan H and Sanlioglu S. Human Gene Therapy. P241. ESGCT and FSGT Collaborative Congress, Helsinki, Finland September 17-20, 2015.
21. Obese and Diabetic Sprague Dawley rats exhibited reduced GLP-1 expression in pancreatic islets of Langerhans. Olgun HB, Tasyurek H, Altunbas HA and Sanlioglu S. Human Gene Therapy. P137. ESGCT and FSGT Collaborative Congress, Helsinki, Finland September 17-20, 2015.
22. In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI animal model of type 2 diabetes. Eksi Y, Tasyurek H, Balci MK and Sanlioglu S. Human Gene Therapy. P228. ESGCT and FSGT Collaborative Congress, Helsinki, Finland September 17-20, 2015.
23. Therapeutic efficacy of an HIV-based lentivirus mediated vasoactive intestinal peptide gene delivery for diabetes. Tasyurek H, Eksi Y, Sanlioglu AD, Balci MK and Sanlioglu S. Human Gene Therapy. P094. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.

24. Construction of A Lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment. Eksi Y, Tasyurek H, Sanlioglu AD, Balci MK and Sanlioglu S. Human Gene Therapy. P123. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.
25. Comparative efficacy of diet induced obesity in C57BL/6J versus Balb/C mice for gene therapy applications. Eksi Y, Tasyurek H, Sanlioglu AD, Balci MK and Sanlioglu S. Human Gene Therapy. P013. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.
26. Induction of Diet Induced Obesity in Sprague Dawley Rats as a Model for Type 2 Diabetes. Eksi Y, Tasyurek H, Altunbas HA and Sanlioglu S. Human Gene Therapy. P014. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.
27. Up-regulation of Glucagon Like Peptide-1 Expression in pancreases of C57BL6J Mice with Diabetes. Tasyurek H, Eksi Y, Altunbas HA, Balci MK and Sanlioglu S. Human Gene Therapy. P021. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.
28. Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes Treatment. Tasyurek H, Eksi Y, Altunbas HA, Balci MK and Sanlioglu S. Human Gene Therapy. P100. ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands 23-26 October 2014.
29. Vasoactive Intestinal Peptide-mediated Gene Therapy for Diabetes. Sanlioglu S. J Pancreas, 2014 Sep 28; 15(5):534
30. Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats. Eksi Y, Tasyurek H, Balik O, Altunbas HA, Balci MK and Sanlioglu S. American Diabetes Association, Diabetes, June 2014 Vol. 63. Suppl. 1. A659, San Francisco, CA, USA.
31. Restoration of Pancreatic Beta Cell Mass and Function by GLP-1 Gene Delivery for Diabetes. Sanlioglu S. Beta Cells in Health and Disease. P13-P14. Kocaeli, Turkey 21-23 May 2014.
32. Pancreatic expression profiles of vasoactive intestinal peptide and its receptors in mouse model of type 2 diabetes. Hapil FZ, Tasyurek MK, Sanlioglu AD, Balci MK and Sanlioglu S. Congress of the European-Society-of-Gene-and-Cell-Therapy/Spanish-Society-of-Cell-and-Gene-Therapy. Abstract P276. Location: Madrid, Spain Date: OCT 25-28, 2013.
33. GLP-1 and GLP-1 receptor expression profiles in pancreatic islets of Diet Induced Obese (DIO) Mice. Tasyurek MK, Hapil FZ, Altunbas HA, Canatan H and Sanlioglu S. Congress of the European-Society-of-Gene-and-Cell-Therapy/Spanish-Society-of-Cell-and-Gene-Therapy. Abstract P277. Location: Madrid, Spain Date: OCT 25-28, 2013.
34. Downregulation of Vasoactive Intestinal Peptide Expression in Type 2 Diabetes. Hapil FZ, Tasyurek MK, Guzel N, Sanlioglu AD, Balci MK and Sanlioglu S. 73. Congress of American Diabetes Association. Diabetes Journal. Vol. 62, Suppl 1, Abstract 2258-P. June 21-25 2013 Chicago IL, USA.
35. Generation of a cost effective and a practical animal model for Type 2 Diabetes. Guzel N, Tasyurek H, Sanlioglu AD, Balci MK and Sanlioglu S. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy Location: Versailles, FRANCE Date: OCT 25-29, 2012. Source: HUMAN GENE THERAPY Volume: 23 Issue: 10 Pages: A78-A79 Published: OCT 2012

36. Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes. Hapil F. Z, Koksoy S., Ersoy F, Kurtoglu E, Undar L and Sanlioglu S. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy Location: Versailles, FRANCE Date: OCT 25-29, 2012. Source: HUMAN GENE THERAPY Volume: 23 Issue: 10 Pages: A115-A116 Published: OCT 2012
37. Pancreatic acinar cells respond differentially to diabetic agents Streptozotocin and Cyclophosphamide. Kahraman S, Dirice E, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy Location: Versailles, FRANCE Date: OCT 25-29, 2012. Source: HUMAN GENE THERAPY Volume: 23 Issue: 10 Pages: A79-A79 Published: OCT 2012
38. Potential Therapeutic Role of Vasoactive Intestinal Peptide in Diabetes. Sanlioglu, AD, Karacay B, Balci MK, Griffith TS and Sanlioglu S. Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy Location: Versailles, FRANCE Date: OCT 25-29, 2012. Source: HUMAN GENE THERAPY Volume: 23 Issue: 10 Pages: Pages: A150-A150 Published: OCT 2012
39. The efficacy of insulin gene therapy in autoimmune diabetes. Sanlioglu S. Molecular Immunology & Immunogenetics Congress, 2012.. Turkish Journal of Immunology. Pages 49-50. Antalya, Turkey
40. Decreased death ligand expression on T lymphocytes of multiple myeloma patients. Hapil F. Z, Koksoy S., Ersoy F, Kurtoglu E, Undar L and Sanlioglu S. Molecular Immunology & Immunogenetics Congress, 2012.. Turkish Journal of Immunology. PP-70. Antalya, Turkey.
41. A novel combinatorial gene therapy modality successfully destroyed synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Yazisiz V, et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X61. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.
42. Efficacy of clinical gene and cell therapy in ADA SCID patients. Bisgin A and Sanlioglu S. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X62. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.
43. In vivo tracing of the most commonly used gene therapy vector. Kahraman S, Dirice E, Sanlioglu AD et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X63. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.
44. In vivo fluorescence tracing of xenogeneic islet graft survival in Type 1 Diabetes. Kahraman S, Dirice E, Hapil FZ et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X64. Clinical Genetics Volume: 78 issue Supplements 1. Page: 129.
45. Clinical genetic significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract H07. Clinical Genetics Volume: 78 issue Supplements 1. Page: 59.
46. Spontaneous type 1 diabetes in NOD mice is related to an increase in DcR1 expression. Kahraman S, Dirice E, Elpek O, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1447-1448 Published: OCT 2010

47. Trail profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients. Bisgin A, Sanlioglu AD, Yoldas B, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1448-1449 Published: OCT 2010
48. In vivo fluorescence imaging of xenogeneic islet graft survival. Kahraman S, Dirice E, Hapil FZ, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1451-1451 Published: OCT 2010
49. STZ administration leads to a significant rise in TRAIL and DcR1 levels in Non-Obese Diabetic (NOD). 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1453-1453 Published: OCT 2010
50. TRAIL expression significantly decreases in CY-accelerated type 1 diabetes in NOD mice. Kahraman S, Dirice E, Elpek O, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1453-1454 Published: OCT 2010
51. The importance of sTRAIL in patients with rheumatoid arthritis. Bisgin A, Terzioglu E, Erbasan F, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1461-1461 Published: OCT 2010
52. The outcome of trail presentation on T cells in patients with multiple myeloma. Hapil FZ, Bisgin A, Aydin C, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1462 Published: OCT 2010
53. Distinctive expression profiles of trail and trail receptors in patients with endometrial carcinoma. Aydin C, Bisgin A, Sanlioglu AD, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1462 Published: OCT 2010
54. Endometrial hyperplasia features distinctive trail and trail receptor expression profiles. Aydin C, Bisgin A, Sanlioglu AD, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1463 Published: OCT 2010
55. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. Bisgin A, Kargi A, Yalcin A, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY. HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1417-1417 Published: NOV 2009
56. Distinctive expression profile of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1422-1423 Published: NOV 2009
57. TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients. Bisgin A, Terzioglu E, Aydin C, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY. HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1471-1471 Published: NOV 2009

58. Adenovirus mediated TRAIL gene therapy approach provides sustained insulin expression in STZ-induced diabetic rats. Dirice E, Sanlioglu A, Kahraman S, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1471-1472 Published: NOV 2009
59. In vivo fluorescence imaging as a method to assess pancreatic islet xenograft failure. Kahraman S, Hapil FZ, Ertosun MG, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1479-1479 Published: NOV 2009
60. Tracing of the fate of allogeneic islet grafts via CCD camera. Kahraman S, Hapil FZ, Aydin C, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1479-1479 Published: NOV 2009
61. Prospective cell and gene therapy approaches designed to extend islet graft survival in patients with type 1 diabetes. Sanlioglu S Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1482-1483 Published: NOV 2009
62. Alterations in TRAIL ligand and receptor expression profiles in CY-accelerated type 1 diabetes in NOD mice. Sanlioglu A, Kahraman S, Dirice E, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1483-1483 Published: NOV 2009
63. Differential levels of TRAIL ligand and receptor expressions in STZ-induced T1 diabetes in non-obese diabetic (NOD) mice. Sanlioglu AD, Dirice E, Kahraman S, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1483-1483 Published: NOV 2009
64. Diagnostic significance of serum sTRAIL in rheumatoid arthritis. Bisgin A, Aydin C, Erbasan F, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1494-1494 Published: NOV 2009
65. Monitoring of systemic delivery of adenovirus mediated EGFP transgene expression in mice using fluorescence imaging. Kahraman S, Dirice E, Sanlioglu A, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1507-1507 Published: NOV 2009
66. A novel gene therapy strategy involving immune-modulation relinquished lymphocyte infiltration into islet grafted sites in STZ induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. OC2.1. 11th European Congress of Endocrinology. 25-29 April 2009, Istanbul, Turkey.

67. Comparative molecular analysis of TRAIL ligand and receptor expression profiles in cyclophosphamide versus streptozotocin-induced diabetes in non-obese diabetic (NOD) mice. Kahraman S, Dirice E, Elpek O, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P336. 11th European Congress of Endocrinology. 25-29 April 2009, Istanbul, Turkey.
68. Cell and gene therapy approaches to prolong islet-graft survival in patients with type 1 diabetes. Dirice E, Sanlioglu AD, Kahraman S, Balci MK, Omer A and Sanlioglu S. Abstract. S13-6. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 314.
69. Genetically engineered pancreatic islets expressing TRAIL extends survival of transplanted pancreatic islets in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK and Sanlioglu S. Abstract. P-60. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 341.
70. In vivo fluorescent imaging of allogeneic and xenogeneic islet grafts following transplantation. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A and Sanlioglu S. Abstract. P-196. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 378-379.
71. Highlights in the molecular pathogenesis of type 1 diabetes. Kahraman S, Dirice E, Elpek O, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P-04. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 324-325.
72. Molecular characterization of TRAIL ligand and receptor expressions in cyclophosphamide-induced type 1 diabetes in NOD mice. Dirice E, Kahraman S, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P-04. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 324-325.
73. Molecular profile of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors on T cells in patients with Rheumatoid Arthritis. Bisgin A, Yazisiz V, Terzioglu E, et al. Abstract. P-04. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 327.
74. The potential use of TRAIL and its receptor expression profile as markers to monitor the prognosis of patients with rheumatoid arthritis. Bisgin A, Terzioglu E, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. P104. World Immune Regulation Meeting-III. 22-25 March 2009, Davos, Switzerland.
75. Serum s TRAIL us efor the assessment of the efficacy of BevacizumAb treatment in metastatic colon cancer. Bisgin A, Kargı A, Yalcin AD, Aydin C, Ekinci D, Terzioglu E, Savas B and Sanlioglu S. Abstract. P-08. JOINT 4th EORTC Pathobiology Group Annual Meeting and 1st International Multidisciplinary Cancer Research Congress. 21-24 May 2009, Antalya, Turkey.
76. CD8+ T cell associated TRAIL DR4 death and DcR1, DcR2 decoy receptors expression correlate with disease severity in patients with rheumatoid arthritis. Bisgin A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. FRI-0065. 10-13 June 2009, Copenhagen, Denmark.
77. Rheumatoid arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptors expression on CD8+ T cells. Bisgin A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. P6-2. 34th FEBS Congress. 4-9 July 2009, Prague, Czech Republic.
78. Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer. Bisgin A, Aydin C, Terzioglu E, Yalcin AD, Kargı A, Savas B and Sanlioglu S. Abstract. P8-18. 34th FEBS Congress. 4-9 July 2009, Prague, Czech Republic.

79. Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu S. Abstract. P17. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1104 November 2008.
80. Prolonged normoglycemia in STZ-induced diabetic rats transplanted with adenovirus-mediated human TRAIL gene (Ad5hTRAIL) infected islets. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. P59. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1119-1120 November 2008.
81. In vivo imaging to detect the duration of adenovirus mediated EGFP transgene expression in allogeneic islet grafts. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. Abstract. P64. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1121-1122 November 2008.
82. Clinical significance of TRAIL and its receptor expression profiles on CD4+ CD25+ Foxp3+ Tregs and CD8+ CD25+ T cells in patients with rheumatoid arthritis. Bisgin A, Yazisiz V, Ulker M, Terzioglu E and Sanlioglu S. Abstract. P134. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1148-1149 November 2008.
83. Soluble TRAIL concentrations in patients with rheumatoid arthritis. Bisgin A, Yazisiz V, Terzioglu E and Sanlioglu S. Abstract. P135. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1149 November 2008.
84. Differential alteration of TRAIL and its receptor expression profiles in patients with pancreatic ductal adenocarcinoma. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. Abstract. 15607. 44th Annual Meeting of American Society of Clinical Oncology. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 15607. Chicago IL USA.
85. High endogenous TRAIL expression level is correlated with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. Abstract. P215. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
86. Adenovirus vectors efficiently deliver TRAIL into pancreatic islets without generating cytotoxic effects. Dirice E, Sanlioglu AD, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. P214. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
87. Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Terzioglu E and Sanlioglu S. Abstract. P258. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
88. Expression profile of TRAIL and its receptors in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. Abstract 2136. European Journal of Cancer. 5 (4) 225-226 September 2007.

89. Testing the efficacy of substance P fragments as antitumor agents. Erin E, Korcum AF, Simsek E, Aydemir E, Sanlioglu S. 6th AFMC International Medicinal Chemistry Symposium. Drugs of the Future. Volume 32. Suppl. A. Abstract PA-45. Istanbul, Turkey, July 8-11 2007.
90. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C., Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. Abstract. P103. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
91. Small interference RNA technology targeting DcR2 sensitized advanced prostate carcinoma cells to adenovirus delivery of TRAIL. Sanlioglu AD, Koksall IT, Karacay B and Sanlioglu S. Abstract. P140. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
92. TRAIL-R4 (DcR2) receptor gene expression is correlated with high Gleason scores, PSA recurrence, and decreased survival in patients with prostate carcinoma. Koksall IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. Abstract. P141. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
93. Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P206. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
94. Electroporation enhances the first generation adenovirus vector transgene delivery into pancreatic islets. Dirice E, Sanlioglu AD, Omer A, Balci MK and Sanlioglu S. Abstract. P208. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
95. Upnormal increase in the nuclear NF-kB activity of the rat cavernosal tissue is correlated with diabetes related erectile dysfunction syndrome. Yoldas B, Usta MF and Sanlioglu S. Abstract. P213. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
96. A DcR2 siRNA approach defeats TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L Ozbilim G, Akdis CA and Sanlioglu S. Abstract. P213. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
97. Differential expression of TRAIL and its receptors in patients with prostate carcinoma. Sanlioglu AD, Koksall IT, Ciftcioglu A, Baykara M, Luleci G, and Sanlioglu S. Abstract. P212. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
98. Adenovirus delivery of TRAIL effectively destroys synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P214. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
99. Adenovirus mediated TRAIL gene delivery as a model for the treatment of patients with diabetes. Dirice E, Sanlioglu AD, Omer A, Balci MK, Terzioglu E and Sanlioglu S. Abstract. P482. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
100. Mechanism of TRAIL resistance in breast cancer cells for adenovirus mediated gene delivery. Koksoy S, Sanlioglu AD, Sanlioglu S. Abstract. 141.19. Annual Meeting of the American Association of Immunologists, Boston, MA, May 12-16, 2006.

101. Surface TRAIL decoy receptor-4 expression constitutes a resistance to adenovirus delivery of TRAIL in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Abstract, P015. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
102. TRAIL ligand and receptor expressions are differentially upregulated in prostate carcinoma patients: a significant issue for gene therapy of advanced prostate cancer. Sanlioglu AD, Koksal IT, Ciftcioglu A, Bassorgun IC, Baykara M, Luleci G, and Sanlioglu S. Abstract. P022. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
103. Decoy receptor gene expression as a chief mechanism to govern TRAIL resistance in advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, and Sanlioglu S. Abstract. P023. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
104. Efficient adenovirus mediated TRAIL gene delivery into pancreatic islets as a model for the treatment of patients with type 1 diabetes. Dirice E, Sanlioglu AD, Omer A, Balci MK and Sanlioglu S. Abstract. P074. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
105. Adenovirus delivery of TRAIL effectively destroys synovial fibroblasts of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P075. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
106. A CTLA-4 exon 1+49 A/A genotype is linked to the clinical progression of systemic lupus erythematosus in patients. Ulker M, Terzioglu E, Yazisiz V and Sanlioglu S. Abstract. P076. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
107. Testing the efficacy of an adenovirus mediated TRAIL gene delivery for the treatment of patients with osteoarthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P078. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
108. A DcR2 siRNA approach overcomes TRAIL resistance in A549 lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L and Sanlioglu S. Abstract. P172. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
109. Adenovirus mediated NF-kB inhibiting strategies for the treatment of patients with type 1 diabetes. Burcak Y and Sanlioglu S. Abstract. P088. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
110. Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type 1 Diabetes. Dirice E. Sanlioglu AD, Koksoy S, Balci MK, Omer A and Sanlioglu S. Abstract. P160. Advances in Molecular Medicine, Istanbul, 2005.
111. Adenovirus mediated TRAIL gene delivery as a gene therapy model for patients with advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. L14. Advances in Molecular Medicine, Istanbul, 2005.
112. A novel gene therapy model for patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Dirice E, Tuzuner S, Koksoy S, Terzioglu E and Sanlioglu S. Abstract. P161. Advances in Molecular Medicine, Istanbul, 2005

113. Adenovirus mediated IKKbKA expression sensitized advanced prostate carcinoma cells to TRAIL-Mediated apoptosis in spite of decoy receptor gene expression. Sanlioglu AD, Koksai IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P165. Advances in Molecular Medicine, Istanbul, 2005.
114. A novel death ligand mediated gene therapy approach for patients with lung cancer. Aydin C, Sanlioglu AD, Dirice E, Dertsiz L, Ozbudak O and Sanlioglu S. Abstract. P162. Advances in Molecular Medicine, Istanbul, 2005.
115. Adenovirus delivery of IKKbKA to liver improves survival in a murine model of endotoxic shock. Yoldas B, Engelhardt JF and Sanlioglu S. Abstract. P167. Advances in Molecular Medicine, Istanbul, 2005.
116. Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Abstract. P164. Advances in Molecular Medicine, Istanbul, 2005.
117. Fundamental principals of Tumor Necrosis Factor-alpha gene therapy approach for patients with lung carcinoma. AD Sanlioglu, C Aydin, H Bozcuk, E Terzioglu and S Sanlioglu Abstract. Or4. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland 2004
118. Anti HIV drug PDTC genotoxic agents synergistically activate Adeno Associated Virus Type-2 endocytosis and transduction. AD Sanlioglu, B Karacay, PK Benson, JF Engelhardt and S Sanlioglu Abstract. P56. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
119. Advanced prostate cancer cells display differential NF-kB activation pattern which is the primary determinant of TRAIL resistance. AD Sanlioglu, IT Koksai, M Baykara, G Luleci, B Karacay and S Sanlioglu Abstract, P19. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
120. Resistance to Adenovirus mediated TRAIL gene therapy in breast cancer cells is eliminated by the expression of dominant negative IKKb. AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P20. 12th Annual Congress of European Society of Gene Therapy Tampere, Finland, 2004
121. Therapeutic effect of recombinant adenovirus mediated TRAIL gene therapy method in Lung Cancer. C Aydin, AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P22. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
122. An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma. Sanlioglu S. Abstract. P38. British Association for Cancer Research (BACR) Conference on Stem cells and Telomerase. Salamis Bay, NC, 2004
123. Adenovirus mediated NF-kB inhibiting gene therapy for breaking down TRAIL resistance observed in advanced prostate carcinoma. Sanlioglu AD, Koksai IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P234. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
124. Gene Expression of a Dominant Negative IKK-beta Mutant in the Liver Improves Survival in a Murine Model of Endotoxic Shock. Sanlioglu S, Williams CM, Sanlioglu AD and Engelhardt JF. Abstract. P269. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
125. TRAIL-Mediated Apoptosis of Neuroblastoma cells is Enhanced by Simultaneous Inhibition of the NF-kB Pathway. Bahri Karacay, Salih Sanlioglu, Thomas S. Griffith, Anthony Sandler, Nicholas J. Pantazis and Daniel J. Bonthius, Neuroscience Meeting, Abstracts, 2003
126. PTEN expression inversely correlates with high Gleason scores and serum PSA levels which are the major prognostic indicators of the advanced prostate carcinoma. Koksai I.T., Dirice E., Yasar D., Ozes O.N., Baykara M.,

- Luleci G., and Sanlioglu S. Abstract. P31. Innovations in the Diagnosis and Treatment of Prostate Cancer, 6th Seminar of the International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer, Antalya-Turkey, 2002
127. PTEN as a diagnostic tool for the prognosis of prostate carcinomas. Dirice E., Koksall I.T., Yasar D., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P745 18th UICC International Cancer Congress. Oslo-Norway, 2002
 128. Abrogation of PTEN expression is crucial for the progression of bladder carcinomas. Yasar D., Koksall T., Dirice E., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P714 18th UICC International Cancer Congress. Oslo-Norway, 2002
 129. A new treatment modality for lung cancer; Differential regulation of Rac1 and IKK pathways sensitizes lung cancer cells to TNF mediated apoptosis. Sanlioglu S., Luleci G. and Thomas K.W. Abstract, Journal of Gene Medicine. P149. 9th Annual Meeting of European Society of Gene Therapy, Antalya, Turkey, 2001
 130. GPx-1 regulated intracellular hydrogen peroxide level specifically modulates IKK-alpha activity. Li Q, Sanlioglu S, Li SJ, Ritchie T, Oberley L, Engelhardt JF. Molecular Biology of the Cell, 12: 1947 Suppl. S NOV 2001
 131. Novel approaches to induce Adeno-associated virus type-2 endocytosis through synergistic activation of Rac1 and PI3K pathways. Sanlioglu S., Benson P., Ritchie T. and Engelhardt J.F. Abstract 522, Molecular Therapy. 4th Annual Meeting of American Society of Gene Therapy, 2001
 132. Regulation of Adeno-Associated Virus Type-2 Endocytosis and Nuclear Trafficking by Rac1/PI3-kinase Pathways. Sanlioglu S., Benson P.K. Yang J., Atkinson E.M., Reynolds T. and Engelhardt J.F. Abstract 348, Molecular Therapy. 3rd Annual Meeting of American Society of Gene Therapy, 2000
 133. ATM gene defect increases the efficiency of adeno-associated virus transductions. Sanlioglu S and Engelhardt J. Abstract 596, Molecular Therapy. 2nd Annual Meeting of American Society for Gene Therapy, 1999.
 134. UV radiation increases the abundance of AAV circular but not replication form intermediates. Sanlioglu S and Engelhardt J. Abstract 227, Pediatric Pulmonology, 1998.
 135. UV radiation and reactive oxygen species augment rAAV transduction through NFkB independent pathways. Sanlioglu S and Engelhardt J. Abstract 226, Pediatric Pulmonology, 1998.
 136. Effect of ectopic En-2 expression in Purkinje cells on development of the cerebellum. Sanlioglu S and Oberdick J. Abstract 121.2, Society for Neuroscience, 1996.
 137. Activation of a Purkinje cell specific gene by homeobox proteins. Sanlioglu S and Oberdick J. Abstract 2000. Molecular Biology of the Cell, 1995.

Domestic Meeting Abstracts

1. İnsülin Gen Tedavisinde Güncel Gelişmeler. Sanlioglu S. 16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Bodrum, Mugla. 27-30 Ekim 2019
2. LentiVİP Gen Nakli Tip 1 Diyabetik Deneklerde Sistemik Enflamasyonu Baskılayarak Kan Şekerini Düşürdü. Erendor F, Sahin EO, Balci MK, and Sanlioglu S. PS052. 16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Bodrum, Mugla. 27-30 Ekim 2019
3. Retinitis Pigmentoza Gen Tedavi Çalışmalarında Kullanılmak Üzere Lentiviral Vektörlerin Geliştirilmesi ve Testi. Sahin EO, Erendor F, Bilgin AB, Ceylaner S, and Sanlioglu S. PS-053. 16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Bodrum, Mugla. 27-30 Ekim 2019
4. Antidiyabetik gen terapi ajanı olarak Glukagon Benzeri Peptid-1 ve hücresel transdiferansiyasyon. Tasyurek HM, Altunbas HA, Sanlioglu S. Bildiri: SS-031 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
5. Antidiyabetik gen nakil çalışmalarında kullanılmak üzere çoklu düşük doz Streptozotosin uygulamasıyla otoimmünitenin indüklendiği Wistar sıçan modelinin geliştirilmesi. Sahin EO, Erendor F, Balci MK, Sanlioglu S. Bildiri: PS-007 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
6. Diyabet hastalığına karşı kullanılmak üzere beta hücre spesifik gen tedavi vektörünün oluşturulması. Erendor F, Sahin EO, Balci MK, Sanlioglu S. Bildiri: PS-008 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
7. 3. jenerasyon HIV tabanlı lentiviral vektörlerin in vivo uygulamalar için üretimi ve pürifikasyon yöntemlerinin optimizasyonu. Olgun HB, Balci MK, Sanlioglu S. Bildiri: PS-010 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
8. İnsülin gen replasman tedavisinde kullanılmak üzere CRISPR- Cas9 yöntemiyle MODY10 diyabetik deney hayvan modeli oluşturma. Eksi YE, Altunbas HA, Sanlioglu S. Bildiri: PS-012 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
9. Tip 1 diyabet için vazoaktif intestinal peptidi kodlayan lentiviral vektörün geliştirilmesi. Erendor F, Sahin EO, Balci MK, Sanlioglu S. Bildiri: PS-014 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
10. İndüklenmiş pluripotent kök hücrelerden insülin sentezini sağlayan gen tedavi vektörünün geliştirilmesi. Gumuslu E, Balci MK, Sanlioglu S. Bildiri: PS-219 15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 26-29 Ekim 2017
11. Diyabette insülin gen tedavi stratejileri. Sanlioglu S. 117-118. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017
12. Diyabet tedavisinde in vivo gen nakil uygulamalarına uygun ölçekte ve kalitede lentiviral vektör üretimi. Olgun HB, Sanlioglu S. SS-06. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017
13. Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması. Tasyurek HM, Eksi YE, Balci MK, Sanlioglu S. SS-09. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017

14. İncretin gen nakli diyabetik deneklerde insülin direncini kırıp glukoz toleransını geliştirerek beta hücre rejenerasyonu sağlar. Tasyurek HM, Altunbas HA, Sanlioglu S. SS-10. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017
15. Diyabet hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere Tip 1 Diyabet hayvan modelinin oluşturulması. Tasyurek HM, Eksi YE, Erendor F, Altunbas HA, Sanlioglu S. SS-11. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017
16. Kök hücre kaynaklı pankreatik beta hücrelerinde uzun süreli insülin gen ekspresyonu yapabilen lentiviral gen tedavi vektörlerinin geliştirilmesi. Gumuslu E, Tasyurek HM, Sanlioglu S. SS-12. 53. Ulusal Diyabet Kongresi. Girne KKTC 19-23 Nisan 2017
17. Diyabet Tedavisinde incretin tabanlı gen tedavi stratejileri. Sanlioglu S. Medical Genetics. Vol 2 Supp 1. Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi. Çeşme, İzmir, 5-9 Ekim 2016.
18. EF-1 promotörü kontrolünde insulin gen ekspresyonu yapan HIV tabanlı lentiviral gen tedavi vektörünün oluşturulması. Tasyurek HM, Eksi YE, Balci MK, Sanlioglu S. Medical Genetics. Vol 2 Supp 1. Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi. Çeşme, İzmir, 5-9 Ekim 2016.
19. Pankreatik beta hücre hedefli HIV tabanlı insülin gen tedavi vektörünün oluşturulması. Eksi YE, Tasyurek HM, Balci MK, Sanlioglu S. Medical Genetics. Vol 2 Supp 1. Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi. Çeşme, İzmir, 5-9 Ekim 2016.
20. Current progress in incretin mediated gene therapy approach. Sanlioglu S. Erciyes Medical Journal. Vol 38 No:1 SP17. Uluslararası Katılımlı Gevher Nesibe Tıp Günleri Tıbbi Genetik ve Klinik Uygulamaları Kongresi. 11-13 Şubat 2016.
21. Diyabet Tedavisinde HIV tabanlı lentivirus aracılı Glukagon Benzeri Peptid-1 gen aktarımının terapötik etkileri Tasyürek H, Altunbas HA, Canatan H ve Sanlioglu S. 14. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 27-30 Ekim 2015
22. GLP1 gen replasman tedavisinin Tip 2 Diyabet Sprague Dawley Sıçanlarda rezidüel adacık replikasyon ve rejenerasyonu üzerindeki etkisinin incelenmesi. Olgun HB, Tasyürek H, Altunbas HA, ve Sanlioglu S. 14. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 27-30 Ekim 2015
23. 3. Jenerasyon Lentivirus aracılı Vazoaktif İntestinal Peptid gen naklinin obezite bağımlı Tip 2 Diyabet deney hayvan modelinde terapötik etkinliği. Sanlioglu S. 14. Ulusal Tıbbi Biyoloji ve Genetik Kongresi. Fethiye, Mugla. 27-30 Ekim 2015
24. HIV tabanlı Lentivirus aracılı Vazoaktif İntestinal Peptid gen nakli obez farelerde insulin direncini kırıp glukoz toleransı geliştirerek STZ indüklü diyabet gelişimini durdurdu. Sanlioglu S. 51. Ulusal Diyabet Kongresi. Antalya. 22-26 Nisan 2015
25. Diyabet tedavisi için insan Glukagon Benzeri Peptid-1 kodlayan lentiviral vektörlerin üretimi. Tasyürek H, Altunbas HA, ve Sanlioglu S. 51. Ulusal Diyabet Kongresi. Antalya. 22-26 Nisan 2015
26. Diyet bağımlı obez Sprague Dawley sıçanlarda STZ ile diyabet indüksiyonu pankreatik adacıklarda incretin hormonu (GLP-1) sentezini azaltır. Olgun HB, Tasyürek H, Altunbas HA, ve Sanlioglu S. 51. Ulusal Diyabet Kongresi. Antalya. 22-26 Nisan 2015

27. Gen tedavisinde kullanılan lentiviral vektörlerin in vivo dağılımlarının Tip 2 Diyabet hayvan modelinde belirlenmesi. Tasyurek HM, Eksi YE, Balci MK, Sanlioglu S. 51. Ulusal Diyabet Kongresi. Antalya. 22-26 Nisan 2015
28. Diyabet tedavisinde inkretin tabanlı gen transfer stratejilerinin yeri. Sanlioglu S. 50. Ulusal Diyabet Kongresi. Antalya. 23-27 Nisan 2014
29. C57BL6J farelerde diyabet indüksiyonu pankreas kökenli GLP-1 sentezini arttırdı. Balık O, Yasyürek H, Eksi YE, Altunbas HA, Balci MK, Sanlioglu S. SS-10. 50. Ulusal Diyabet Kongresi. Antalya. 23-27 Nisan 2014
30. C57BL6J fareler diyetle Sprague Dawley sıçanlara kıyasla daha hızlı ve etkin prediabet gelişimi gösterdi. Eksi YE, Yasyurek H, Balık O, Altunbas HA, Balci MK, Sanlioglu S. SS-11. 50. Ulusal Diyabet Kongresi. Antalya. 23-27 Nisan 2014
31. Diyabet hastalığına karşı geliştirilen insan vazoaktif intestinal peptid kodlayan HIV tabanlı gen transfer vektörlerinin yapımı ve testi. Tasyurek HM, Balık O, Eksi YE, Altunbas HA, Balci MK, Sanlioglu S. SS-12. 50. Ulusal Diyabet Kongresi. Antalya. 23-27 Nisan 2014
32. Diyabette Vazoaktif Intestinal Peptidin terapotik rolu. Sanlioglu AD, Karacay B, Altunbas HA, Balci MK, Griffith TS ve Sanlioglu S. OP12. 49. Ulusal Diyabet Kongresi. Antalya. 17-21 Nisan 2013
33. Tip 2 diyabet deney hayvan modelinde diyabet induksiyonu adacıklarda vazoaktif intestinal peptid azalimiyla korelasyon gosterdi. Hapil FZ, Tasyurek H, Guzel N, Sanlioglu AD, Balci MK ve Sanlioglu S. OP20. 49. Ulusal Diyabet Kongresi. Antalya. 17-21 Nisan 2013
34. Rexin G, the first and the only targetted gene delivery vehicle developed to seek out and destroy metastatic cancer cell to date. Hapil FZ and Sanlioglu S. Turkiye Klinikleri J Med Sci 2011;31 (Suppl) S15. XII Ulusal Tibbi Biyoloji ve Genetik Kongresi. Antalya. 27-30 Ekim 2011
35. Death Ligand Expression Profiles on Cytotoxic Lymphocytes of Multiple Myeloma Patients. Hapil FZ, Guzel N, Salim O, Koksoy S, Dundar L ve Sanlioglu S. Turkiye Klinikleri J Med Sci 2011;31 (Suppl) S109. XII Ulusal Tibbi Biyoloji ve Genetik Kongresi. Antalya. 27-30 Ekim 2011
36. NOD farelerde streptozotosin veya siklofosamid ile hizlandirilmis Tip 1 Diyabet gelism surecinde pankreatik asinar hucrelerde farkli TRAIL ligand ve reseptor paternleri. Dirice E, Kahraman S, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S and Sanlioglu AD. Turkiye Klinikleri J Med Sci 2011;31 (Suppl) S187. XII Ulusal Tibbi Biyoloji ve Genetik Kongresi. Antalya. 27-30 Ekim 2011.
37. Apoptoz yoluyla deneysel adacik naklinde hucrel immun sistemi bertaraf edebilen yeni bir strateji. Sanlioglu S. Hucre olumu arastirma teknikleri kursu. Izmir. 24-25 Kasim 2011.
38. Tip 1 Diyabette gen ve hucre tedavisinin yeri. Sanlioglu S. 33. Turkiye Endokrinoloji ve Metabolizma Hastaliklari Kongresi. Antalya. 12-16 Ekim 2011.
39. Allojenik ve xenojenik pankreatik adacik transplantasyon basarisinin in-vivo floresan görüntülemeyle takibi. Kahraman S., Dirice E., Hapil FZ., Ozturk S., Griffith TS., Sanlioglu AD., Sanlioglu S. 46. Ulusal Diyabet Kongresi, Abstrakt SS05, Antalya, 12-16 Mayıs 2010.
40. Non-obese diabetic (NOD) farelerde streptozotosin veya siklofosamid ile indüklenen diyabette T1D'in moleküler patogenezinin aydınlatılmasına yönelik bulgular. Sanlioglu AD., Kahraman S., Dirice E., Elpek O., Aydin C., Balci MK., Omer A., Sanlioglu S. 46. Ulusal Diyabet Kongresi, Abstrakt SS06, Antalya, 12-16 Mayıs 2010.

41. TRAIL ve reseptörlerinin yassı hücreli larenks ve oral kavite kanserleriyle ilişkisi. Yoldaş B, Ozer C, Ozen O, Canpolat T, Dogan I, Sanlioglu S ve Ozluoglu LN. 31. Ulusal Kulak Burun Bogaz ve Bas ve Boyun Cerrahisi Kongresi. 28 Ekim-1 Kasım 2009. Antalya, Türkiye.
42. Sistemik adenovirus aracılı gen nakli in vivo olarak CCD kameralar ile başarıyla görüntülenebilir. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Bagcı H, Erkıılıç M, Griffith TS ve Sanlioglu S. S32. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
43. Ex vivo adenovirus aracılı EGFP gen aktarımı yapılan pankreatik adacık ksenotransplantasyon başarısı CCD kamera ile belirlendi. Kahraman S, Dirice E, Sanlioglu AD, Hapil FZ, Balcı MK, Omer A, Griffith TD and Sanlioglu S. S39. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
44. Serum sTRAIL konsantrasyonunun romatoid artrit tanısındaki yeri. Bisgin A, Aydın C, Erbasan F, Terzioğlu E ve Sanlioglu S. P145. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
45. Tip 1 diyabette alloimmune mononükleer hücre infiltrasyonun gen tedavisiyle baskılanması fonksiyonel adacık-graft ömrünü uzatır. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balcı MK, Griffith TS and Sanlioglu S. Abstrak. 45. Ulusal Diyabet Kongresi. 20-24 Mayıs 2009, Antalya, Türkiye.
46. Diyabetik farelere sıçan pankreatik adacıklarının ksenotransplantasyonu normoglisemi sağlamaktadır. Kahraman S, Dirice E, Sanlioglu AD, Omer A, Balcı MK, Griffith TS and Sanlioglu S. Abstrak. 45. Ulusal Diyabet Kongresi. 20-24 Mayıs 2009, Antalya, Türkiye.
47. BevacizumAb tedavisi uygulanan kolon kanserli hastalarda sTRAIL düzeyinin artışı sağ kalım süresi ile ilişkilidir. Bisgin A, Aydın C, Yalcin AD, Kargı A, Ekinci D, Terzioğlu E, Savas B ve Sanlioglu S. Bildiri Ref. No:P410. XVIII. Ulusal Kanser Kongresi. 21-26 Nisan 2009, Antalya, Türkiye.
48. In vivo fluorescent imaging of adenovirus delivery of reporter gene expression for allogeneic islet transplantation. Kahraman S, Dirice E, Sanlioglu AD, Balcı MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 11, İstanbul, 29 Mayıs-1 Haziran 2008.
49. Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets provides prolonged normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balcı MK, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 10, İstanbul, 29 Mayıs-1 Haziran 2008.
50. The success of rat islet isolation mainly relies on complete pancreas inflation. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balcı MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 4, İstanbul, 29 Mayıs-1 Haziran 2008.
51. Gene therapy application scenarios to prolong islet-graft survival in patients with type 1 diabetes: Kahraman S, Dirice E, Sanlioglu AD, Balcı MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract, İstanbul, 29 Mayıs-1 Haziran 2008.
52. Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balcı MK, Griffith TS, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 5, İstanbul, 29 Mayıs-1 Haziran 2008.

53. Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 3, Istanbul, 29 Mayıs-1 Haziran 2008.
54. Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Yazisiz V, Terzioğlu E, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 14, Istanbul, 29 Mayıs-1 Haziran 2008.
55. Pankreatik adacıklarda adenoviral vektor aracili transgen sentez suresinin in vivo olarak CCCD kamera ile goruntulenmesi. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
56. Pankreatik adaciklara adenovirus aracili insan TRAIL geni (Ad5hTRAIL) aktarimi STZ induklemeli diyabetik sicanlarda uzun sureli normoglisemi saglar. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
57. Tip 1 diyabet hastalarinda gerceklestirilen adacik naklinde graft sagkalimini uzatabilecek gen tedavi senaryolari: Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
58. Pankreatik adacik izolasyon basarisini artirmaya yonelik yapilan deneysel bir calisma: Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
59. Pankreatik duktal adenokarsinomali hastalarda trail olum reseptoru-4 (DR4) ve yalanci reseptor-2'nin (DCR2) ekspresyonlarindaki artis, artan hucre olumleri ile iliskilidir. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
60. TRAILING from molecular diagnostics to prostate cancer gene therapy. Sanlioglu AD, Koksall IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. XIX Ulusal İmmunoloji Kongresi, Abstract, Antalya, 21-24 Kasım 2007.
61. Yokluğu Tip 1 diyabetle ilişkilendirilmiş TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, PS54, Antalya, 9-13 Mayıs 2007.
62. Tip 1 diyabetli hastalarda kullanılacak etkin bir tedavi modelinin geliştirilmesi maksadıyla pankreatik adacıklara adenovirus aracılı TRAIL geni aktarımı. Dirice E, Sanlioglu AD, Ömer A, Balci MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, PS51, Antalya, 9-13 Mayıs 2007.
63. Tip 1 diyabette ölümcül ligant aracılı gen tedavi modelinin moleküler etki mekanizması. Sanlioglu AD, Dirice E, Ömer A, Terzioğlu E, Sarı R, Balci MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, Antalya, 9-13 Mayıs 2007.
64. Tip 1 diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili ve artan apoptozis ile korelasyonu. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P112, Antalya, 6-9 Eylül 2007.

65. Adenoviral vektörler sitotoksik etki oluşturmada pankreatik adacıklara etkin TRAIL gen aktarımı sağlar. Dirice E, Sanlioglu AD, Ömer A, Balcı MK, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P134, Antalya, 6-9 Eylül 2007.
66. Adenovirus aracılı TRAIL transferi osteoartritli hastalardan izole edilmiş normalde apoptoza dirençli sinovyal fibroblastları yok etti. Bisgin A, Sanlioglu AD, Tuzüner S, Terzioglu E and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P153, Antalya, 6-9 Eylül 2007.
67. Potential therapeutic efficacy of adenovirus delivery of TRAIL for patients with prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract K11, Antalya, 6-9 Eylül 2007.
68. Adenovirus aracılı ölümcül ligand transferinin gen tedavisindeki yeri. Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract K19, Manisa, 2005.
69. İleri evre prostat kansinomada yalancı reseptör gen ekspresyonu TRAIL dirençliliğinin ortaya çıkmasında önemli bir faktördür. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Griffith TS and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P12, Manisa, 2005
70. Adenovirus aracılı TRAIL gen transferinin romatoid artritli hastalıklardaki terapötik etkisi. Bisgin A, Sanlioglu AD, Ulker M, Tuzüner S, Terzioglu E and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P41, Manisa, 2005.
71. Tip 1 diyabetli hastalar için geliştirilen pankreatik adacık transplantasyonunda adenovirus aracılı TRAIL gen transferinin etkinliği. Dirice E, Sanlioglu AD, Ömer A, Balcı MK, and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P66, Manisa, 2005.
72. DcR2 siRNA yaklaşımı A549 akciğer kanser hücrelerini adenovirus aracılı TRAIL transferine duyarlı kılar. Aydın C, Sanlioglu AD, Özbudak Ö, Dertsiz L and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract AG05, Manisa, 2005.
73. The implication of adenovirus mediated death ligand gene delivery for human gene therapy. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, and Sanlioglu S. XVIII. Ulusal İmmunoloji Kongresi, Abstract, Antalya, 2005.
74. Current Progress in Cancer Gene Therapy. Sanlioglu S. XIX Ulusal Biyokimya Kongresi, Abstract K05, Antalya, 2005.
75. Hücre içi anti-apoptotik yolun bloke edilmesi meme kanserini adenovirus aracılı TRAIL gen tedavi metoduna karşı duyarlı hale getirdi. Sanlioglu AD, Dirice E, and Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P127, İstanbul, 2004.
76. Akciğer kanserinde recombinant adenovirus aracılı TRAIL gen tedavi metodunun terapötik etkisi. Aydın C, Sanlioglu AD, Dirice E, and Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P128, İstanbul, 2004.
77. An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma. Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P135, İstanbul, 2004.
78. Akciğer kanserinde yeni bir adenovirus aracılı TNF-alpha gen tedavi metodu. Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, KSB 08, Antalya, 2004.

79. İleri evre prostat kanserinde NFkB yolunun bloke edilmesi TRAİL dirençliliğini kırar. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, MP 27, Antalya, 2004.
80. Karaciğerde adenovirus aracılı dominant negative IKK beta mutandının gen sentezi endotoksik şoktan hayatta kalma süresini arttırır. Sanlioglu S and Engelhardt JF. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, MP 47, Antalya, 2004.
81. İleri evre meme kanserinin adenovirus aracılı TRAİL gen tedavi metoduna duyarlılaştırma yöntemleri. Sanlioglu AD, Dirice E, and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, KP 04, Antalya, 2004.
82. PTEN ekspresyon düzeyinin mesane kanseri gelişimindeki rolü. Yasar D, Koksal IT, Dirice E, Özeş ON, Baykara M, Karauzum SB, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P558, Antalya, 2003.
83. Prostat kanserli olgularda PTEN ekspresyonunun prognostic değeri. Dirice E Koksal IT, , Yasar D, Özeş ON, Baykara M, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P559, Antalya, 2003.
84. Gen tedavisinde güncel gelişmeler. Sanlioglu S and Sanlioglu AD. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract, Adana, 2003.
85. Adenovirus aracılı TRAİL geni aktarımının prostat karsinomanın farklı evreleri üzerindeki etkinliği ve prostat kanserli hastalarda TRAİLe olan direnci kırmak için yeni gen tedavi metotlarının geliştirilmesi. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract ÖS-3, Adana, 2003.
86. Mesane kanser gelişiminde PTENin prognostik değerinin belirlenmesi. Yasar D, Koksal IT, Dirice E, Karauzum SB, Çifçioğlu A, Baykara M, Özeş ON, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi. Abstract SS-4, Adana, 2003.
87. PTENin Gleson skoru ve PSAYA kıyasla prostat kanserindeki prognostik değerinin belirlenmesi. Dirice E Koksal IT, Yasar D, Sanlioglu AD, Çifçioğlu A, Gülkesen KH, Özeş ON, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract SS-5, Adana, 2003.

Domestic Publications in Turkish

- Kök hücrelerde programlanabilir nükleazlarla genom mühendisliği uygulamaları ve yeni bir insülin gen nakli hastalık modeli oluşturma. Eksi YE, Sanlioglu S. Türkiye Klinikleri, Stem Cell and Transplantation Immunology Özel Sayı, 2019, p:79-88.
- FDA Onaylı İlk Onkolitik Viral Terapi Ajanı Talimogene Laherparepvec'in (IMLYGICTM) Öyküsü. Eksi YE, Sanlioglu S. Türkiye Klinikleri J Med Genet-Special Topics 2016;1(2):80-89
- Inkretin Tabanlı Tedavi Stratejilerinde Komplikasyon Kaygıları ve Senaryoları. Sanlioglu S. Klinik Tıp Bilimleri Dergisi, Clinical Medical Sciences, Diyabet özel sayısı. Nisan 2014 2(1):19-24
- Tip 1 diyabetli hastalarda insulin tedavisinde ve insulin gen terapisinde güncel gelişmeler. Sanlioglu AD, Altunbas HA, Balci MK, Sanlioglu S. Klinik Tıp Bilimleri Dergisi, Clinical Medical Sciences, Diyabet özel sayısı. Nisan 2012 1-5
- Gen Tedavisinin Dünyü Bugünü ve Yarını. Sanlioglu S. TÜBİTAK Bilim Teknik. Aralık 2009 38-43

Book Chapters in Turkish

- İnsülin Gen Naklinin Geçmiş ve Geleceği (Gen ve Hücre Tedavisinde Güncel Gelişmeler). Erendor F, Eksi YE, Sanlioglu S. Türkiye Klinikleri Tıbbi Genetik. Ankara. 20.01.2021 Online ISBN: 978-625-401-228-0. p.33-44.
- Tasarımdan beta hücre rejenerasyonuna Insulin Gen Nakli. Eksi YE, Tasyurek HM, Sanlioglu AD, Altunbas HA, Balci MK, Sanlioglu S. Year Book of Turkish Diabetology 2017-2018. Pages 289-304
- Gen Tedavisi. Sanlioglu S. Tıbbi Genetik ve Klinik Uygulamaları. 2017 20: 497-522.
- Diyabet tedavisinde inkretin tabanlı gen tedavi stratejileri. Sanlioglu S. Geçmişten geleceğe Diabetes Mellitis. 2015 603-614.
- Gen Tedavisi. Caglayan AO ve Sanlioglu S. Modern Biyoteknoloji ve Uygulamaları. 2010 180: 631-644.